• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Fanapt Falls Flat! Link from the Street.com

Quote




Anonymous said:
Latuda is moving because they are promoting it off label. Now, management tells the Fanapt reps to hit every psych regardless of their schizophrenia volume. That is wink, wink, for off label promotion of other indications.

Why risk a massive fine for a product that is never going to take off?
Click to expand...

You arent going to get a massive fine for a drug that nobody prescribes, Genius. You ever hear of Big Tobacco? The government comes after those that achieve an economic profit (look it up). They want to get their cut.

Nobody is EVER going to prescribe Fanapt. We could go in there and say "for your patients eating turtle heads while skydiving, prescribe Fanapt" and get the results we are getting now.

LOOK FOR ANOTHER JOB!

You should have been doing it for months.

BTW--Someone should have sent in this question the other day--"Does anyone have Jeff Kruikshank's cell phone number?"
 




Anonymous said:
You arent going to get a massive fine for a drug that nobody prescribes, Genius. You ever hear of Big Tobacco? The government comes after those that achieve an economic profit (look it up). They want to get their cut.

Nobody is EVER going to prescribe Fanapt. We could go in there and say "for your patients eating turtle heads while skydiving, prescribe Fanapt" and get the results we are getting now.

LOOK FOR ANOTHER JOB!

You should have been doing it for months.

BTW--Someone should have sent in this question the other day--"Does anyone have Jeff Kruikshank's cell phone number?"
Click to expand...

From the casual observer: "Who is Jeff Kruikshank and why is he important?" Was he a major player on the Fanapt team and now he has left the company? That is my gut feel..........
 




Former Novartis here, yes laid off. I have a new job but I am curious what you guys are doing these days. I heard from another former Novartis Neuropsych rep that you guys are selling Fanapt, Exelon Patch, Stalevo and Comtan.

How is it going selling the entire portfolio? Any hope that this will save a few jobs?
 








Anonymous said:
This is probably a valid post. In the Vanda trials lack of efficacy was the key issue why Vanda could never get FDA approval. They turned over the data to Novartis who helped them massage it through the FDA. You have to wonder if there were some greased palms along the way!
Click to expand...

Novartis has the cash to get things done! However, they can't force a Doc to prescribe a dog drug!
 




Can't think of a drug , in any therapeutic catgegory, that was 8th or 9th in its class that was successful at all. There are examples of 3rd, 4th, or 5th drugs to class being successful but I think in all cases they were "better mousetraps" in some form or another. More convenient dosing, greater potency, better side effect profile, etc. Plus you can't "buy" the business anymore with gimmicks like NCN ( Novartis Consultant Network) trips with families to nice resorts etc. Why would a doc prescribe a drug with complicated bid dosing, heightened hopotensive warnings and if you actually dig into the studies, less efficacy than risperidone in schizophrenia. Oh, and have had to report a number of patients with weight gain.
 




I have talked to three different Neuropsych reps who have heard rumors of a downsizing of the Neuropsych division in December.

They are upstanding reps and not the type to make up stories. They are all from different regions of the country. Funny that they all mentioned the same thing.

What is the consensus from everyone else about December 2011?
 




Anonymous said:
I have talked to three different Neuropsych reps who have heard rumors of a downsizing of the Neuropsych division in December.

They are upstanding reps and not the type to make up stories. They are all from different regions of the country. Funny that they all mentioned the same thing.

What is the consensus from everyone else about December 2011?
Click to expand...

Summer...!
 




Anonymous said:
I have talked to three different Neuropsych reps who have heard rumors of a downsizing of the Neuropsych division in December.

They are upstanding reps and not the type to make up stories. They are all from different regions of the country. Funny that they all mentioned the same thing.

What is the consensus from everyone else about December 2011?
Click to expand...

If Novartis follows form, December 2011 it is!
 
































Anonymous said:
This is probably a valid post. In the Vanda trials lack of efficacy was the key issue why Vanda could never get FDA approval. They turned over the data to Novartis who helped them massage it through the FDA. You have to wonder if there were some greased palms along the way!
Click to expand...

My guess would be that you are exactly correct!
 












Top Bottom
Back
Quote